Chinese Journal of Pharmacovigilance ›› 2025, Vol. 22 ›› Issue (5): 592-595.
DOI: 10.19803/j.1672-8629.20240857

Previous Articles     Next Articles

Research Progress in Uric Acid-Lowering Drugs

YAN Caiying1, QIN Linying1, XU Yaoqing2, WANG Xinge3, CHAI Nannan4, CHEN Long1,4,*   

  1. 1School of Pharmacy, Zunyi Medical University, Zunyi Guizhou 563000, China;
    2School of Nursing, Yingtan Health Vocational College, Yingtan Jiangxi 335000, China;
    3School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan 611137, China;
    4School of Nursing, Chifeng University, Chifeng Inner Mongolia 024000, China
  • Received:2024-11-01 Online:2025-05-15 Published:2025-05-19

Abstract: Objective To explore the research progress in uric acid-lowering drugs so as to provide a reference for their clinical applications. Methods By accessing the official websites of the National Medical Products Administration, China National Knowledge Infrastructure (CNKI), Wanfang Database and PubMed, information was collected on the safety of uric acid-lowering drugs, including urate transporter 1 (URAT1) inhibitors, xanthine oxidase (XO) inhibitors and exogenous uricase, which were used in the treatment of chronic gout between April 1, 2014, and September 1, 2024. In addition, the key information on 27 uric acid-lowering drugs currently under development was analyzed using the Cortellis platform. Results The adverse reactions of URAT1 inhibitors mostly involved the digestive system, manifested as liver function abnormalities. The adverse reactions caused by XO inhibitors and exogenous uric acid oxidases primarily manifested themselves as skin and mucous membrane damage and blood system damage, such as immunogenic reactions and serious cardiovascular events. The targets of action for most of the currently-developed anti-gout drugs were URAT1 inhibitors, which increased the excretion of uric acid while reducing the incidence of gout. Conclusion Although three types of drugs are usually used for the treatment of chronic gout, the potential adverse reactions remain a concern. Future research and development of anti-gout drugs should focus on dual-target or new-target drugs with unique advantages in order to offer more options for the clinical treatment of patients.

Key words: Chronic Gout, Uric Acid-Lowering Drugs, URAT1 Inhibitors, XO Inhibitors, Exogenous Uric Acid Oxidase, Adverse Drug Reactions

CLC Number: